Nature Communications (Jan 2017)

Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome

  • Cara Lunn Shirai,
  • Brian S. White,
  • Manorama Tripathi,
  • Roberto Tapia,
  • James N. Ley,
  • Matthew Ndonwi,
  • Sanghyun Kim,
  • Jin Shao,
  • Alexa Carver,
  • Borja Saez,
  • Robert S. Fulton,
  • Catrina Fronick,
  • Michelle O’Laughlin,
  • Chandraiah Lagisetti,
  • Thomas R. Webb,
  • Timothy A. Graubert,
  • Matthew J. Walter

DOI
https://doi.org/10.1038/ncomms14060
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 10

Abstract

Read online

Spliceosome mutations occur in approximately 50% of patients with myelodysplastic syndromes. Here, the authors show that tumour cells harbouring theS34F mutation in the U2AFspliceosome gene is sensitive to compounds that further perturb the spliceosome.